Login to Your Account

Amylin Obesity Trial Stopped Due to Safety Questions

By Catherine Shaffer

Thursday, March 17, 2011
Amylin Pharmaceuticals Inc. and Takeda Pharmaceutical Co. Ltd. have become the latest drugmakers to be stymied by safety signals in clinical trials of an obesity candidate. The companies have suspended an ongoing study of pramlintide/metreleptin for obesity.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription